Evotec bags US$45m upfront in Celgene dealNeurology specialist Celgene has nailed down access to Evotec’s induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases. more ➔
Grifols confirms €1.75bn acquisition in...Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit. more ➔
Oncology: Orion teams up with Wi2 Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance. more ➔
Curetis bags EIB debt financing and expand... Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive … more ➔
Crenezumab data support Amyloid-beta targe... While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further … more ➔
TxCell gains Treg rightsFrench immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive … more ➔
Researchers report ubiquitous cancer targe...UK researchers have identified a highly conserved target structure that can be directed to rush dividing cancer cells into premature division and cell death. more ➔
Merck expands portfolio of liquid biopsy t...Merck KGaA has expanded its portfolio of blood-based RAS diagnostics for use in patient stratification. After kicking off testing with Sysmex Inostics’ CE-marked OncoBEAM RAS CRC liquid biopsy … more ➔
TiGenix launches IPO in the USEuronext Brussels-noted adipose stem cell player TiGenix NV wants to offer 2.75 million American Depositary Shares (ADS) in an IPO at Nasdaq Global Market representing 55 million of its ordinary shares … more ➔
Roche licenses Novimmune’s anti-TLR4...Roche’s US subsidiary Genentech has acquired an exclusive option to commercialise Novimmune’s TLR4 antibody NI-0101, the very first personalised approach to treat rheumatoid arthritis. The compound has … more ➔
